報價延遲最少15分鐘:2025/01/12 06:15 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.41 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.17/-1.20
|
|
企業價值
78.36M
|
| 資產負債 |
|
每股賬面淨值
0.59
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/12 06:15 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. |